
China's Henlius inks $301 M deal with Sandoz for proposed Ipilimumab biosimilar
China's Henlius inks $301 M deal with Sandoz for proposed Ipilimumab biosimilar May 2, 2025 | Friday | News Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations Shanghai …